Post-Hoc Analysis Confirms Consistent Clinical Benefit With Olaparib Plus Abiraterone in HRR-Mutated mCRPC
Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.
Stay updated with breaking news from Exact Imaging. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.
IRVINE, Calif. and SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- A correction has been issued for a release issued under the same headline earlier today...
25.04.2023 - IRVINE, Calif. and SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) - A correction has been issued for a release issued under the same headline earlier today by Clinical Laserthermia Systems Americas, Inc. The complete and corrected release follows: ... Seite 1
ST. LOUIS, Aug. 02, 2022 -- Stereotaxis , a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the significant enhancement of its...
Stereotaxis announced today that it appointed two new vice presidents who both have extensive industry experience.